VaxigripTetra Suspension zur injektion in einer fertigspritze

Land: Schweiz

Sprache: Deutsch

Quelle: Swissmedic (Swiss Agency for Therapeutic Products)

Wirkstoff:

haemagglutininum influenzae A (H1N1) (Virus souche A/Victoria/4897/2022 (H1N1)pdm09-like: reassortant virus IVR-238 derived from A/Victoria/4897/2022), haemagglutininum influenzae A (H3N2) (Virus souche A/Darwin/9/2021 (H3N2)-like: reassortant virus IVR-228 derived from A/Darwin/9/2021), haemagglutininum influenzae B (Virus souche B/Austria/1359417/2021-like: B/Michigan/01/2021, wilde type (Victoria lineage))

Verfügbar ab:

Sanofi-Aventis (Suisse) SA

ATC-Code:

J07BB02

INN (Internationale Bezeichnung):

haemagglutininum influenzae A (H1N1) (Virus souche A/Victoria/4897/2022 (H1N1)pdm09-like: reassortant virus IVR-238 derived from A/Victoria/4897/2022), haemagglutininum influenzae A (H3N2) (Virus souche A/Darwin/9/2021 (H3N2)-like: reassortant virus IVR-228 derived from A/Darwin/9/2021), haemagglutininum influenzae B (Virus souche B/Austria/1359417/2021-like: B/Michigan/01/2021, wilde type (Victoria lineage))

Darreichungsform:

Suspension zur injektion in einer fertigspritze

Zusammensetzung:

haemagglutininum influenzae A (H1N1) (Virus souche A/Victoria/4897/2022 (H1N1)pdm09-like: reassortant virus IVR-238 derived from A/Victoria/4897/2022) 15 µg, haemagglutininum influenzae A (H3N2) (Virus souche A/Darwin/9/2021 (H3N2)-like: reassortant virus IVR-228 derived from A/Darwin/9/2021) 15 µg, haemagglutininum influenzae B (Virus souche B/Austria/1359417/2021-like: B/Michigan/01/2021, wilde type (Victoria lineage)) 15 µg, haemagglutininum influenzae B (Virus souche B/Phuket/3073/2013-like: B/Phuket/3073/2013, wilde type (Yamagata lineage)) 15 µg, natrii chloridum, kalii chloridum, dinatrii phosphas dihydricus, kalii dihydrogenophosphas, aqua ad iniectabile q.s. ad suspensionem pro 0.5 ml corresp. natrium 1.72 mg, kalium 0.08 mg, residui: formaldehydum, octoxinolum-9, neomycinum, ovalbuminum.

Klasse:

B

Therapiegruppe:

Impfstoffe

Therapiebereich:

Aktive immunisierung gegen influenza, ab dem 6. monat

Berechtigungsstatus:

zugelassen

Berechtigungsdatum:

2018-06-12